Secondary infiltration of the central nervous system in patients with diffuse large B-cell lymphoma
OBJECTIVE: To investigate the incidence and risk factors of infiltration of the central nervous system after the initial treatment of diffuse large B-cell lymphoma in patients treated at Santa Casa de Misericórdia de São Paulo. METHODS: A total of 133 patients treated for diffuse large B-cell lymphoma from January 2001 to April 2008 were retrospectively analyzed in respect to the incidence and risk factors of secondary central nervous system involvement of lymphoma. Intrathecal prophylaxis was not a standard procedure for patients considered to be at risk. This analysis includes patients whether they received rituximab as first-line treatment or not. RESULTS: Nine of 133 (6.7%) patients developed central nervous system disease after a mean observation time of 29 months. The median time to relapse or progression was 7.9 months after diagnosis and all but one patient died despite the treatment administered. Twenty-six (19.5%) patients of this cohort received rituximab as first-line treatment and nine (7.1%) received intrathecal chemoprophylaxis. Of the nine patients that relapsed, seven (77.7%) had parenchymal central nervous system involvement; seven (77.7%) had stage III or IV disease; one (11.1%) had bone marrow involvement; two (22.2%) had received intrathecal chemoprophylaxis; and 3 (33.3%) had taken rituximab. In a multivariate analysis, the risk factors for this infiltration were being male, previous use of intrathecal chemotherapy and patients that were refractory to initial treatment. CONCLUSION: Central nervous system infiltration in this cohort is similar to that of previous reports in the literature. As this was a small cohort with a rare event, only three risk factors were important for this infiltration
Main Authors: | , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
2013
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842013000400256 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S1516-84842013000400256 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S1516-848420130004002562013-10-10Secondary infiltration of the central nervous system in patients with diffuse large B-cell lymphomaRocha,Talita Maira Bueno da Silveira daCosta,Fortier SergioPinto,Maeva Seo GomesSilva,Igor Campos daPaes,Roberto PintoChiattone,Carlos Sergio Lymphoma, large B-cell, diffuse Central nervous system neoplasms/secondary Doxorubicin/administration & dosage Drug administration schedule Antineoplastic Agents/therapeutic use Multivariate analysis Risk factors OBJECTIVE: To investigate the incidence and risk factors of infiltration of the central nervous system after the initial treatment of diffuse large B-cell lymphoma in patients treated at Santa Casa de Misericórdia de São Paulo. METHODS: A total of 133 patients treated for diffuse large B-cell lymphoma from January 2001 to April 2008 were retrospectively analyzed in respect to the incidence and risk factors of secondary central nervous system involvement of lymphoma. Intrathecal prophylaxis was not a standard procedure for patients considered to be at risk. This analysis includes patients whether they received rituximab as first-line treatment or not. RESULTS: Nine of 133 (6.7%) patients developed central nervous system disease after a mean observation time of 29 months. The median time to relapse or progression was 7.9 months after diagnosis and all but one patient died despite the treatment administered. Twenty-six (19.5%) patients of this cohort received rituximab as first-line treatment and nine (7.1%) received intrathecal chemoprophylaxis. Of the nine patients that relapsed, seven (77.7%) had parenchymal central nervous system involvement; seven (77.7%) had stage III or IV disease; one (11.1%) had bone marrow involvement; two (22.2%) had received intrathecal chemoprophylaxis; and 3 (33.3%) had taken rituximab. In a multivariate analysis, the risk factors for this infiltration were being male, previous use of intrathecal chemotherapy and patients that were refractory to initial treatment. CONCLUSION: Central nervous system infiltration in this cohort is similar to that of previous reports in the literature. As this was a small cohort with a rare event, only three risk factors were important for this infiltration info:eu-repo/semantics/openAccessAssociação Brasileira de Hematologia e Hemoterapia e Terapia CelularRevista Brasileira de Hematologia e Hemoterapia v.35 n.4 20132013-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842013000400256en10.5581/1516-8484.20130094 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Rocha,Talita Maira Bueno da Silveira da Costa,Fortier Sergio Pinto,Maeva Seo Gomes Silva,Igor Campos da Paes,Roberto Pinto Chiattone,Carlos Sergio |
spellingShingle |
Rocha,Talita Maira Bueno da Silveira da Costa,Fortier Sergio Pinto,Maeva Seo Gomes Silva,Igor Campos da Paes,Roberto Pinto Chiattone,Carlos Sergio Secondary infiltration of the central nervous system in patients with diffuse large B-cell lymphoma |
author_facet |
Rocha,Talita Maira Bueno da Silveira da Costa,Fortier Sergio Pinto,Maeva Seo Gomes Silva,Igor Campos da Paes,Roberto Pinto Chiattone,Carlos Sergio |
author_sort |
Rocha,Talita Maira Bueno da Silveira da |
title |
Secondary infiltration of the central nervous system in patients with diffuse large B-cell lymphoma |
title_short |
Secondary infiltration of the central nervous system in patients with diffuse large B-cell lymphoma |
title_full |
Secondary infiltration of the central nervous system in patients with diffuse large B-cell lymphoma |
title_fullStr |
Secondary infiltration of the central nervous system in patients with diffuse large B-cell lymphoma |
title_full_unstemmed |
Secondary infiltration of the central nervous system in patients with diffuse large B-cell lymphoma |
title_sort |
secondary infiltration of the central nervous system in patients with diffuse large b-cell lymphoma |
description |
OBJECTIVE: To investigate the incidence and risk factors of infiltration of the central nervous system after the initial treatment of diffuse large B-cell lymphoma in patients treated at Santa Casa de Misericórdia de São Paulo. METHODS: A total of 133 patients treated for diffuse large B-cell lymphoma from January 2001 to April 2008 were retrospectively analyzed in respect to the incidence and risk factors of secondary central nervous system involvement of lymphoma. Intrathecal prophylaxis was not a standard procedure for patients considered to be at risk. This analysis includes patients whether they received rituximab as first-line treatment or not. RESULTS: Nine of 133 (6.7%) patients developed central nervous system disease after a mean observation time of 29 months. The median time to relapse or progression was 7.9 months after diagnosis and all but one patient died despite the treatment administered. Twenty-six (19.5%) patients of this cohort received rituximab as first-line treatment and nine (7.1%) received intrathecal chemoprophylaxis. Of the nine patients that relapsed, seven (77.7%) had parenchymal central nervous system involvement; seven (77.7%) had stage III or IV disease; one (11.1%) had bone marrow involvement; two (22.2%) had received intrathecal chemoprophylaxis; and 3 (33.3%) had taken rituximab. In a multivariate analysis, the risk factors for this infiltration were being male, previous use of intrathecal chemotherapy and patients that were refractory to initial treatment. CONCLUSION: Central nervous system infiltration in this cohort is similar to that of previous reports in the literature. As this was a small cohort with a rare event, only three risk factors were important for this infiltration |
publisher |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular |
publishDate |
2013 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842013000400256 |
work_keys_str_mv |
AT rochatalitamairabuenodasilveirada secondaryinfiltrationofthecentralnervoussysteminpatientswithdiffuselargebcelllymphoma AT costafortiersergio secondaryinfiltrationofthecentralnervoussysteminpatientswithdiffuselargebcelllymphoma AT pintomaevaseogomes secondaryinfiltrationofthecentralnervoussysteminpatientswithdiffuselargebcelllymphoma AT silvaigorcamposda secondaryinfiltrationofthecentralnervoussysteminpatientswithdiffuselargebcelllymphoma AT paesrobertopinto secondaryinfiltrationofthecentralnervoussysteminpatientswithdiffuselargebcelllymphoma AT chiattonecarlossergio secondaryinfiltrationofthecentralnervoussysteminpatientswithdiffuselargebcelllymphoma |
_version_ |
1756423566739374080 |